Business course

NVAX ALERT: Investors with Substantial Losses Have the Option to pursue the Novavax, Inc. class action lawsuit.


SAN DIEGO – (COMMERCIAL THREAD) –Robbins Geller Rudman & Dowd LLP announces that purchasers of securities of Novavax, Inc. (NASDAQ: NVAX) between March 2, 2021 and October 19, 2021 inclusive (the “Class Period”) have until January 11, 2022 to solicit appointment as applicant main in Sinnathurai v. Novavax, Inc., No. 21-cv-02910 (D. Md.). Filed on November 12, 2021 and pending before Judge Theodore D. Chuang, the Novavax The class action lawsuit accuses Novavax and some of its senior executives of violations of the Securities Exchange Act of 1934.

If you wish to serve as the principal applicant of the Novavax class action, please fill in your information by clicking here. You can also contact the lawyer JC Sanchez from Robbins Geller by calling 800 / 449-4900 or emailing [email protected] Principal applicant’s requests for Novavax The class action must be filed with the court no later than January 11, 2022.

CASE ALLEGATIONS: Novavax is a biotechnology company with product candidates including, among others, NVX-CoV2373, which is under development as a vaccine against COVID-19. Prior to the start of the remedy period, Novavax announced that it plans to complete Emergency Use Authorization (“EUA”) applications for NVX-CoV2373 with the United States Food and Drug Administration. during the second quarter of 2021.

The Novavax The class action alleges that, throughout the Class Period, the Defendants made false and misleading statements and failed to disclose that: (i) Novavax overestimated its manufacturing capabilities and downplayed manufacturing issues that would have an impact. impact on its approval schedule for NVX-CoV2373; (ii) as a result, Novavax was unlikely to meet the EUA regulatory timelines for NVX-CoV2373; (iii) as a result, Novavax overestimated the regulatory and commercial outlook for NVX-CoV2373; and (iv) therefore, Novavax’s public statements were materially false and misleading at all relevant times.

May 10, 2021, The Washington Post reported that Novavax’s EUA filing “was delayed by manufacturing regulatory issues, until June at the earliest, according to four people who had recently been briefed on the company’s plans.” Later today, during a call to investors, Novavax confirmed that it is unlikely to seek an EUA for NVX-CoV2373 in the United States until July 2021 at the earliest – that is to say, the third quarter of 2021. On this news, the Novavax share price fell by almost 9%. In addition, following a call to Novavax investors, the Novavax share price continued to fall by 13.9%.

Then, on August 5, 2021, Novavax announced that it plans to file the EUA of NVX-CoV2373 in the fourth quarter of 2021, rather than in the third quarter of 2021. On this news, the Novavax share price fell by more than 19%.

Finally, on October 19, 2021, Politics published an article titled “They Rushed the Process”: Woes of Vaccine Manufacturers Hinder Global Inoculation Campaign. ” The Politics The article reported, in a relevant section, that Novavax “faces significant hurdles in proving that it can manufacture shot that meets regulator quality standards” with respect to NVX-CoV2373. The Politics The article quoted anonymous sources saying that “Novavax’s issues are more of a concern than previously thought” and that Novavax could take until the end of 2022 to resolve its manufacturing issues and obtain regulatory clearances and approvals. . Following this news, the Novavax share price fell a further 14.7%, harming investors even more.

THE MAIN COMPLAINANT PROCESS: The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Novavax securities during the Recourse Period to seek appointment as principal plaintiff in the Novavax class action lawsuit. A principal plaintiff is generally the plaintiff with the greatest financial interest in the remedy sought by the putative class which is also typical and adequate of the putative class. A lead applicant acts on behalf of all other class members by ordering Novavax class action lawsuit. The lead plaintiff can choose a law firm of their choice to litigate the Novavax class action lawsuit. The ability of an investor to participate in any potential future recovery of the Novavax to classify legal action does not depend on serving as the principal plaintiff.

ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: With 200 attorneys in 9 offices across the country, Robbins Geller Rudman & Dowd LLP is the largest US law firm representing investors in securities class actions. Robbins Geller lawyers have secured many of the largest shareholder recoveries in history, including the largest securities class action recovery ever – $ 7.2 billion – in In re Enron Corp. Dry. Litigation. The 2020 ISS Securities Class Action Services Top 50 report ranked Robbins Geller # 1 for recovering $ 1.6 billion from investors last year, more than double the amount recovered by any other company from securities claimants. Please visit http://www.rgrdlaw.com for more information.

Lawyer advertising.

Past results do not guarantee future results.

Services can be performed by lawyers in one of our offices.

https://www.linkedin.com/company/rgrdlaw

https://twitter.com/rgrdlaw

https://www.facebook.com/rgrdlaw